title: Otago Glaucoma Surgery Outcome Study: follow-up of young patients who underwent Molteno implant surgery.
abstract: OBJECTIVE
  To provide data on the results of patients with nonneovascular juvenile glaucoma who had Molteno implant surgery in the province of Otago, New Zealand.
  
  
  METHODS
  Prospective noncomparative case series.
  
  
  METHODS
  Fifty-five operations in 52 eyes of 45 patients with nonneovascular juvenile glaucoma who had Molteno implant surgery between the ages of 9 and 49 years from 1976 to 2003 at Dunedin Hospital and were observed for a mean of 12.2 years (range, 0.1-25).
  
  
  METHODS
  Insertion of a Molteno implant.
  
  
  METHODS
  Intraocular pressure (IOP) and visual acuity (VA).
  
  
  RESULTS
  Insertion of a Molteno implant controlled IOP at < or =21 mmHg with probabilities of 0.89 (95% confidence interval [CI], 0.81-0.97) at both 1 and 2 years and 0.85 (95% CI, 0.75-0.95), 0.78 (95% CI, 0.66-0.90), and 0.71 (95% CI, 0.58-0.85) at 5, 10, and 15 years, respectively. Mean VA was 20/100 preoperatively; improved to 20/60 at 1 year; and stabilized at 20/120 at 5, 10, and 15 years postoperatively. Twenty-nine eyes had their preoperative VA maintained or improved at final follow-up, and the VAs of 17 eyes deteriorated but were at least light perception at final follow-up.
  
  
  CONCLUSIONS
  The use of Molteno implants in cases of nonneovascular juvenile glaucoma controlled IOP with a probability of 0.71 15 years postoperatively, whereas 53% maintained or improved their vision from their preoperative VA at final follow-up.
authors.affiliation: Eye Department, Dunedin Hospital, Dunedin, New Zealand.
authors.forename: John J
authors.initials: JJ
authors.lastname: Ah-Chan
authors.forename: Anthony C B
authors.initials: AC
authors.lastname: Molteno
authors.forename: Tui H
authors.initials: TH
authors.lastname: Bevin
authors.forename: Peter
authors.initials: P
authors.lastname: Herbison
mesh_terms: D000293:Adolescent; D000328:Adult; D017668:Age of Onset; D000959:Antihypertensive Agents / Q000008:administration & dosage; D002648:Child; D005260:Female; D005355:Fibrosis / Q000517:prevention & control; D005500:Follow-Up Studies; D005901:Glaucoma / Q000503:physiopathology / Q000601:surgery*; D006801:Humans; D007429:Intraocular Pressure / Q000502:physiology; D007431:Intraoperative Complications; D008297:Male; D008875:Middle Aged; D018465:Molteno Implants; D009520:New Zealand; D011183:Postoperative Complications; D011446:Prospective Studies; D019919:Prosthesis Implantation; D016896:Treatment Outcome; D014792:Visual Acuity / Q000502:physiology
chemical_list: D000959:Antihypertensive Agents